With 0.54 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.77 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.2424 whereas the lowest price it dropped to was $0.2285. The 52-week range on CLDI shows that it touched its highest point at $3.89 and its lowest point at $0.20 during that stretch. It currently has a 1-year price target of $10.00. Beta for the stock currently stands at 0.93.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CLDI was up-trending over the past week, with a rise of 1.87%, but this was down by -32.40% over a month. Three-month performance dropped to -58.01% while six-month performance fell -82.54%. The stock lost -79.66% in the past year, while it has lost -88.31% so far this year. A look at the trailing 12-month EPS for CLDI yields -1.84 with Next year EPS estimates of -0.32. For the next quarter, that number is -0.11. This implies an EPS growth rate of 84.85% for this year and 28.89% for next year.
Float and Shares Shorts:
At present, 31.79 million CLDI shares are outstanding with a float of 29.70 million shares on hand for trading. On 2025-06-13, short shares totaled 0.37 million, which was 114.99999999999999 higher than short shares on 1747267200. In addition to Mr. Andrew C. Jackson as the firm’s Chief Financial Officer, Ms. Wendy Pizarro Campbell Esq. serves as its Chief Legal, Chief Corporate Dev, Chief Diversity & Corp Sec..
Institutional Ownership:
Through their ownership of 0.17245 of CLDI’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, CLDI reported revenue of $0.0 and operating income of -$5012000.0. The EBITDA in the recently reported quarter was -$4628000.0 and diluted EPS was -$0.18.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With CLDI analysts setting a high price target of 10.0 and a low target of 10.0, the average target price over the next 12 months is 10.0. Based on these targets, CLDI could surge 4247.83% to reach the target high and rise by 4247.83% to reach the target low. Reaching the average price target will result in a growth of 4247.83% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$3.695 being high and -$3.695 being low. For CLDI, this leads to a yearly average estimate of -$3.695. Based on analyst estimates, the high estimate for the next quarter is -$0.1 and the low estimate is -$0.1. The average estimate for the next quarter is thus -$0.1.
